Pharma
-
{
- All
- News
- Videos
- Web Stories
-
Natco Pharma Q2 Results: Net Profit Falls 61% To Rs 203 Crore, Revenue Declines 29%; Stock Tumbles 3%
At the operating level, earnings before interest, taxes, depreciation and amortisation (EBITDA) fell 55.4% to Rs 258.3 crore, compared with Rs 579 crore a year ago.
-
Cancer Drug Prices Slashed By Up To 96.45%; Annual Consumer Savings Pegged At Rs 3,540 Crore: Government
The government on Monday said revised prices of 1,364 anti-cancer drug formulations have come into effect, with consumers expected to save an estimated Rs 3,540.38 crore annually following a cap on trade margins for 137 anti-cancer drugs.
-
Government Cancer Drug Price Curb Likely To Create Rs 3,357 Crore Savings Estimate
India's move to cap trade margins on 137 non-scheduled anti-cancer medicines has led 70 companies to cut maximum retail prices by an average 20 per cent to 70 per cent on 120 medicines, with estimated patient savings of Rs 3,357.49 crore, an official factsheet said on Friday.
-
Sun Pharma Gets Approval For Semaglutide Pill In India: How Will This Impact Diabetes Treatment?
The pill's active ingredient (raw material) will be sourced from China's Hangzhou-province-based Zhongmeihuadong Pharmaceutical.
-
Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform
Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.
-
Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%
Mankind Pharma's September-quarter performance was supported by 15.9% growth in domestic pharmaceutical revenue, excluding consumer healthcare, to Rs 3,428 crore. However, performance in consumer healthcare will remain key monitorable.
-
Mankind Pharma Q2 Results: Net Profit Jumps 39% To Rs 711 Crore, Margin Expands
Mankind Pharma reported a 39.1% year-on-year rise in Q2 net profit to Rs 711 crore, while revenue grew 17.3% to Rs 4,338 crore.
-
How A Rs 276 Stock Turned Into A Rs 20,000 Multibagger: Do You Own It?
A Rs 1 lakh investment in Neuland Laboratories at Rs 276 per share would be worth around Rs 72.5 lakh at Rs 20,000, excluding dividends, taxes, and transaction costs. The pharma company’s earnings growth and changing business profile help explain its multibagger journey.
-
Bet On Banks, Pharma For Q2 Earnings Growth, Says Tushar Bohra Of Invexa Capital; Flags Crude, Currency Risks
Bohra said the current market momentum is being driven by active stock-picking, while elevated crude oil prices and currency movements remain key concerns for the market.
-
Russian Drone Strike Destroys Indian-Owned Pharma Unit In Ukraine, One Dead
The Kusum Group describes itself as a Ukrainian company with Indian roots and sells mostly generic medicines across several countries.
-
Novartis, China's Abogen Ink $7.8 Billion Deal For mRNA Therapies
Abogen will receive $575 million upfront, with up to $7.2 billion in milestone payments tied to clinical development, approvals and commercial milestones.
-
Sun Pharma To Commercialise Novel Bad Cholesterol Drug Lerodalcibep In Ex-US, China Markets
Sun Pharma will commercialise and manufacture lerodalcibep in global markets outside the US and China after securing exclusive rights from LIB Therapeutics.
-
Exclusive: After Survey Flags 2,800% Pharma Profit, Tukaram Mundhe Calls For Transparency
While pharma or any other industry will not work to incur losses, Tukaram Mundhe said there needs to be transparency. "A trade margin of 2800 per cent is not acceptable, either as a consumer or as a hospital or as a regulator," he told NDTV.
-
Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler
The USFDA approval for Aurobindo Pharma's first metered-dose inhaler takes its cumulative ANDA approvals to 596, strengthening its complex product portfolio.
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
-
Natco Pharma Q2 Results: Net Profit Falls 61% To Rs 203 Crore, Revenue Declines 29%; Stock Tumbles 3%
At the operating level, earnings before interest, taxes, depreciation and amortisation (EBITDA) fell 55.4% to Rs 258.3 crore, compared with Rs 579 crore a year ago.
-
Cancer Drug Prices Slashed By Up To 96.45%; Annual Consumer Savings Pegged At Rs 3,540 Crore: Government
The government on Monday said revised prices of 1,364 anti-cancer drug formulations have come into effect, with consumers expected to save an estimated Rs 3,540.38 crore annually following a cap on trade margins for 137 anti-cancer drugs.
-
Government Cancer Drug Price Curb Likely To Create Rs 3,357 Crore Savings Estimate
India's move to cap trade margins on 137 non-scheduled anti-cancer medicines has led 70 companies to cut maximum retail prices by an average 20 per cent to 70 per cent on 120 medicines, with estimated patient savings of Rs 3,357.49 crore, an official factsheet said on Friday.
-
Sun Pharma Gets Approval For Semaglutide Pill In India: How Will This Impact Diabetes Treatment?
The pill's active ingredient (raw material) will be sourced from China's Hangzhou-province-based Zhongmeihuadong Pharmaceutical.
-
Sun Pharma Brokerage Review: Citi, HSBC Maintain Buy; BofA Retains Underperform
Ilumya's US sales challenges, higher R&D spending, and the growth prospects of Leqselvi and Unloxcyt remain key factors shaping brokerage views on Sun Pharma.
-
Mankind Pharma Shares Jump Nearly 8% After Q2 Profit Rises 39%
Mankind Pharma's September-quarter performance was supported by 15.9% growth in domestic pharmaceutical revenue, excluding consumer healthcare, to Rs 3,428 crore. However, performance in consumer healthcare will remain key monitorable.
-
Mankind Pharma Q2 Results: Net Profit Jumps 39% To Rs 711 Crore, Margin Expands
Mankind Pharma reported a 39.1% year-on-year rise in Q2 net profit to Rs 711 crore, while revenue grew 17.3% to Rs 4,338 crore.
-
How A Rs 276 Stock Turned Into A Rs 20,000 Multibagger: Do You Own It?
A Rs 1 lakh investment in Neuland Laboratories at Rs 276 per share would be worth around Rs 72.5 lakh at Rs 20,000, excluding dividends, taxes, and transaction costs. The pharma company’s earnings growth and changing business profile help explain its multibagger journey.
-
Bet On Banks, Pharma For Q2 Earnings Growth, Says Tushar Bohra Of Invexa Capital; Flags Crude, Currency Risks
Bohra said the current market momentum is being driven by active stock-picking, while elevated crude oil prices and currency movements remain key concerns for the market.
-
Russian Drone Strike Destroys Indian-Owned Pharma Unit In Ukraine, One Dead
The Kusum Group describes itself as a Ukrainian company with Indian roots and sells mostly generic medicines across several countries.
-
Novartis, China's Abogen Ink $7.8 Billion Deal For mRNA Therapies
Abogen will receive $575 million upfront, with up to $7.2 billion in milestone payments tied to clinical development, approvals and commercial milestones.
-
Sun Pharma To Commercialise Novel Bad Cholesterol Drug Lerodalcibep In Ex-US, China Markets
Sun Pharma will commercialise and manufacture lerodalcibep in global markets outside the US and China after securing exclusive rights from LIB Therapeutics.
-
Exclusive: After Survey Flags 2,800% Pharma Profit, Tukaram Mundhe Calls For Transparency
While pharma or any other industry will not work to incur losses, Tukaram Mundhe said there needs to be transparency. "A trade margin of 2800 per cent is not acceptable, either as a consumer or as a hospital or as a regulator," he told NDTV.
-
Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler
The USFDA approval for Aurobindo Pharma's first metered-dose inhaler takes its cumulative ANDA approvals to 596, strengthening its complex product portfolio.
-
India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth
A majority of companies within Nomura's coverage universe outpaced the broader pharma market in August. Zydus Lifesciences and Glenmark Pharmaceuticals posted the strongest YoY value expansion.
